NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP
Bruker Corporation BRKR
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.4B
▲ 2.1% vs FY2024
EPS · FY25
$-0.15
Dividend / sh · FY25
—
Payout · FY25
-265%
ROE · FY25
-0.4%
Net margin · FY25
-0.3%
Dividend coverage
3.8×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.4B
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 0 cents on every revenue dollar this year.
Per share
USD -0.15
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 3.8 times — the rest stayed in the company.
Profitability
-0.4%
Return on equity, FY2025
ROE
Operating margin2.0%
Net margin-0.3%
Return on assets-0.1%
Each USD of equity lost 0 cents this year.
Returned to shareholders
USD 24.9M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 22.8M
Net buybacksUSD 2.1M
Share of profit-289.5%
Consecutive raises—
USD 22.8M in dividends and USD 2.1M in buybacks went back to shareholders in a year without profit.
Growth
+11.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+10.7%
+11.6%
+7.8%
+6.7%
Dividend / share
+7.7%
+4.6%
Returned to shareholders
−55.9%
−29.6%
−10.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.15B
Shares outstanding, FY2025
Change, 5 years+0.1%
Change, 10 years−8.0%
The share count grew 0% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 6.2B
total assets, end of FY2025
Total assetsUSD 6.2B
EquityUSD 2.5B
CashUSD 298.8M
Gross debtUSD 1.9B
Net debtUSD 1.6B
Current ratio1.73×
Net debt stands at 63% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
3.4
3.4
3.0
2.5
2.4
2.0
2.1
1.9
1.8
1.6
1.6
1.8
1.8
1.8
1.7
1.3
1.1
Operating income $B
0.1
0.3
0.4
0.4
0.4
0.2
0.3
0.3
0.2
0.2
0.1
0.1
0.1
0.2
0.2
0.2
0.1
EBITDA $B
0.3
0.4
0.6
0.5
0.5
0.3
0.4
0.3
0.3
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
Income tax $B
0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.1
0.1
0.1
0.0
Net income $B
−0.0
0.1
0.4
0.3
0.3
0.2
0.2
0.2
0.1
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
EPS, diluted $
−0.15
0.76
2.90
1.99
1.81
1.02
1.26
1.14
0.49
0.95
0.60
0.33
0.48
0.46
0.55
0.58
0.49
Dividend / sh $
·
0.20
0.20
0.20
0.16
0.16
0.16
0.16
0.16
0.16
·
·
·
·
·
·
·
Payout %
−265
27
7
10
9
16
13
14
32
17
·
·
·
·
·
·
·
ROE %
−0.4
7.2
34.3
27.2
27.3
16.9
21.9
22.2
11.1
21.7
13.6
7.0
10.3
11.7
16.1
18.2
·
Shares out B
0.15
0.15
0.15
0.15
0.15
0.15
0.15
0.16
0.16
0.16
0.17
0.17
0.17
0.17
0.17
0.17
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed